Day One Biopharmaceuticals to Engage at Healthcare Conference
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN), a dedicated biopharmaceutical leader in developing targeted therapies for life-threatening diseases, is gearing up for an important event. They have recently announced their participation in a fireside chat at an annual healthcare conference, aiming to shed light on their innovative approaches to pediatric cancer treatment.
Fireside Chat Details
The fireside chat is scheduled for a set date and time. This interactive session will allow the management team of Day One to discuss their vision and strategy directly with the audience. The panel will be conducted live, creating an engaging opportunity for stakeholders and potential investors to learn more about the company's mission.
Accessing the Live Broadcast
For those interested in the discussion, a live webcast will be available. Attendees can access it easily through the Events & Presentations section on Day One's Investors & Media webpage. Additionally, an archived version of the webcast will be available for 30 days after the event, ensuring that everyone has the opportunity to catch up on insights they may have missed.
Day One’s Commitment to Pediatric Cancer
Day One Biopharmaceuticals was established to confront a significant challenge in healthcare: the lack of therapeutic developments targeting pediatric cancer. Their dedication stems from a belief that outcomes can be improved for children diagnosed with cancer. Inspired by the critical conversations that take place at the beginning of a child’s cancer journey, Day One strives to reshape the landscape of cancer treatment from the very first day.
Innovative Pipeline of Treatments
Day One partners with top clinical oncologists, families, and researchers to carefully select and develop vital cancer treatments. Their current pipeline includes promising therapies like tovorafenib (branded as OJEMDA™), DAY301, and an innovative program surrounding a VRK1 inhibitor. Each treatment represents a step towards addressing unmet medical needs in pediatric oncology.
Company Overview and Philosophy
Headquartered in Brisbane, California, Day One Biopharmaceuticals combines passion and expertise to redefine cancer drug development. Their mission focuses on delivering solutions that cater to individuals of all ages afflicted by cancer, with a strong emphasis on the pediatric population.
Engagements in Public Discourse
The company actively utilizes various channels such as their Investor Relations website, social media handles, and professional networking sites to communicate transparently with stakeholders. This includes sharing news and updates on corporate performance, sharing event details, and fulfilling their obligation to disclose essential nonpublic information.
Contact Information for Day One
For media inquiries, Laura Cooper serves as the Head of Communications and can be reached by email. For investor relations, LifeSci Advisors representative PJ Kelleher is available for queries. Both emphasize their willingness to connect and share insights about the company's progress and future endeavors.
Frequently Asked Questions
1. What is the main purpose of the fireside chat?
The fireside chat aims to provide updates on Day One Biopharmaceuticals' strategies and innovations in pediatric cancer treatments, allowing interaction with stakeholders.
2. How can the public access the live webcast?
The live webcast can be accessed on Day One’s Investors & Media webpage under the Events & Presentations section.
3. What therapies are currently being developed by Day One?
The pipeline includes tovorafenib (OJEMDA™), DAY301, and a VRK1 inhibitor program, specifically targeting pediatric cancer treatment.
4. Where is Day One Biopharmaceuticals located?
Day One Biopharmaceuticals is located in Brisbane, California, where it focuses on developing innovative therapies for cancer.
5. Who can I contact for more information about investor relations?
For investor relations inquiries, you can reach PJ Kelleher from LifeSci Advisors via email to discuss the company’s developments.
